| Income Statement | 2025-09-30 | 2025-03-31 | 2024-09-30 | |
|---|---|---|---|---|
| Revenue | 100 | - | - | |
| Research and development | 3,550 | 1,906 | 1,305 | |
| General and administrative | 2,501 | 2,973 | 2,801 | |
| Total operating expenses | 6,051 | 4,879 | 4,106 | |
| Operating loss | -5,951 | -4,879 | -4,106 | |
| Interest income | 267 | 72 | 174 | |
| Interest expense | 36 | 54 | 57 | |
| Total other income | 231 | 18 | 117 | |
| Net loss from continuing operations | - | -4,861 | -3,989 | |
| Loss from discontinued operations | - | 0 | - | |
| Net loss | -5,720 | -4,861 | -3,989 | |
| Other comprehensive loss - unrealized loss on debt securities | -15 | - | - | |
| Comprehensive loss | -5,735 | - | - | |
| Earnings per share, basic | -0.11 | -0.49 | -0.46 | |
| Earnings per share, diluted | -0.11 | -0.49 | -0.46 | |
| Weighted average number of shares outstanding, basic | 52,981,000 | 9,862,000 | 8,633,000 | |
| Weighted average number of shares outstanding, diluted | 52,981,000 | 9,862,000 | 8,633,000 | |
iBio, Inc. (IBIO)
iBio, Inc. (IBIO)